A new study in the UK will investigate the long-term effects of lung inflammation and scarring from COVID-19, Imperial College London announced on Wednesday.
After battling COVID-19, many patients experience long-term symptoms of lung damage, including breathlessness, coughing, fatigue and limited ability to exercise.
The inflammation in the lungs may improve over time, but in some people it persists and in severe cases the lungs may become scarred, Imperial explained.
Supported by GBP2m of funding from UK Research and Innovation (UKRI), the researchers at Imperial aim to develop treatment strategies to prevent the development of severe scarring and disability following COVID-19.
(USD1=GBP0.73)
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib